Vaxcyte, Inc.
PCVX· Nasdaq
Released Aug 6, 2024, after the close
10-Q filed Aug 6, 2024, 37 days after period end · 0001649094-24-000052
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$128.70M | -$68.34M | -$48.53M | -$23.68M |
| EPS Diluted | -$1.10 | -$0.70 | -$0.80 | -$0.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR